Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Current Assets: 2019-2024

Historic Current Assets for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Dec 2024 value amounting to $434.9 million.

  • 4D Molecular Therapeutics' Current Assets fell 38.84% to $312.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $312.4 million, marking a year-over-year decrease of 38.84%. This contributed to the annual value of $434.9 million for FY2024, which is 46.65% up from last year.
  • 4D Molecular Therapeutics' Current Assets amounted to $434.9 million in FY2024, which was up 46.65% from $296.6 million recorded in FY2023.
  • In the past 5 years, 4D Molecular Therapeutics' Current Assets registered a high of $434.9 million during FY2024, and its lowest value of $220.5 million during FY2022.
  • In the last 3 years, 4D Molecular Therapeutics' Current Assets had a median value of $296.6 million in 2023 and averaged $317.3 million.
  • As far as peak fluctuations go, 4D Molecular Therapeutics' Current Assets skyrocketed by 438.31% in 2020, and later declined by 13.96% in 2022.
  • Yearly analysis of 5 years shows 4D Molecular Therapeutics' Current Assets stood at $282.7 million in 2020, then declined by 9.33% to $256.3 million in 2021, then decreased by 13.96% to $220.5 million in 2022, then surged by 34.50% to $296.6 million in 2023, then surged by 46.65% to $434.9 million in 2024.